Loading clinical trials...
Loading clinical trials...
A Multicenter Prospective Observational Study to Evaluate the Safety and Efficacy of Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years
Conditions
Locations
1
China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Start Date
December 30, 2020
Primary Completion Date
December 30, 2023
Completion Date
July 30, 2024
Last Updated
June 6, 2022
NCT06043011
NCT05098613
NCT07272499
NCT07257510
NCT06846489
NCT04792489
Lead Sponsor
Peking University Third Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions